Plasma Proteome Profiling for Lung Cancer Biomarker Discovery

Lung cancer is the leading cause of cancer-related deaths worldwide, yet studying the disease has remained challenging due to the complex etiological factors of the disease. To shed new light into lung cancer diagnosis and clinical outcomes, Bruce Wilcox, Ph.D., Chief Technology Officer, PrognomiQ, Inc., embarked on a study to interrogate the biological phenomics landscape of blood plasma and identify new biomarkers capable of detecting early-stage lung cancer. The scientific endeavour, leveraging Seer’s Proteograph™ workflow for untargeted plasma proteomics analysis, is one of the largest multi-omics observational studies ever conducted. Dr. Wilcox and Eric Chen, Ph.D., Marketing Application Scientist, Seer Inc., will share insights into the landmark study, the true power of multi-omics to characterize complex diseases, and how the Proteograph workflow provided unprecedented resolution to the underlying biology of lung cancer. On May 23, join us as we explore significant achievements and technological advancements in cancer diagnostics: • Comprehensive Multi-Omics Analysis: Learn how this ground study identified 113,671 peptides, 219,729 RNA transcripts, and more, using an advanced platform for comprehensive profiling of blood-based biomarkers. • Exceptional Diagnostic Accuracy: Discover how the multi-omics classifier achieved an impressive diagnostic accuracy with an AUC of 0.96 for detecting all-stage lung cancer and 0.93 for early-stage detection. • Innovative Non-invasive Approaches: Gain insights into non-invasive methods for early lung cancer detection through the application of multi-omics platforms that analyse proteins and molecular analytes from blood samples. • Broad Clinical Utility: Discover a multi-omics approach that helps facilitate population-wide studies aimed at identifying new biomarkers for various clinical applications.